We are live on ! Find out more
OCMI

Oaktop Capital Management II Portfolio holdings

AUM $2.35B
1-Year Est. Return 214.39%
This Fund
S&P 500
This Quarter Est. Return
+14.63%
1 Year Est. Return
+214.39%
3 Year Est. Return
+451.11%
5 Year Est. Return
+528.04%
10 Year Est. Return
+2,709.82%
AUM
$381M
AUM Growth
-$103M
Cap. Flow
-$144M
Cap. Flow %
-37.77%
Top 10 Hldgs %
93.19%
Holding
20
New
3
Increased
–
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$31.8M
2
SONO icon
Sonos
SONO
+$5.57M
3
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$923K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$182M
2
NTRP
Neurotrope, Inc. Common
NTRP
+$95K

Sector Composition

Rank Sector Weight
1 Technology 80.31%
2 Healthcare 12.51%
3 Materials 5.28%
4 Miscellaneous 1.86%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRCX icon
1
Lam Research
LRCX
$337B
$92.5M 24.28%
3,165,040
– –
KLAC icon
2
KLA
KLAC
$219B
$71.4M 18.74%
4,007,500
– –
MXIM
3
DELISTED
Maxim Integrated Products
MXIM
$45.7M 11.98%
742,375
– –
BMY icon
4
Bristol-Myers Squibb
BMY
$130B
$35.6M 9.35%
+554,991
New +$31.8M
PRGS icon
5
Progress Software
PRGS
$1.72B
$25.4M 6.68%
612,526
– –
CEVA icon
6
CEVA Inc
CEVA
$783M
$21.4M 5.62%
793,836
– –
ASPN icon
7
Aspen Aerogels
ASPN
$409M
$20.1M 5.28%
2,593,272
– –
EGAN icon
8
eGain
EGAN
$141M
$20.1M 5.27%
2,536,843
– –
VMW
9
DELISTED
VMware, Inc
VMW
$14M 3.68%
92,500
– –
PETS icon
10
PetMed Express
PETS
$34.7M
$8.79M 2.31%
373,675
– –
DELL icon
11
Dell
DELL
$358B
$7.23M 1.9%
277,441
– –
SONO icon
12
Sonos
SONO
$1.85B
$6.25M 1.64%
+400,000
New +$5.57M
XLE icon
13
State Street Energy Select Sector SPDR ETF
XLE
$42B
$6M 1.58%
200,000
– –
AXDX
14
DELISTED
Accelerate Diagnostics
AXDX
$2.62M 0.69%
15,500
– –
INTC icon
15
Intel
INTC
$534B
$1.98M 0.52%
33,010
– –
BMY.RT
16
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$1.07M 0.28%
+354,991
New +$923K
ANIK icon
17
Anika Therapeutics
ANIK
$279M
$648K 0.17%
12,500
– –
NXH
18
Neighborhood Intelligence Inc
NXH
$324M
$174K 0.05%
32,825
– –
NTRP
19
DELISTED
Neurotrope, Inc. Common
NTRP
– –
-116,845
Closed -$95K
CELG
20
DELISTED
Celgene Corp
CELG
– –
-1,833,957
Closed -$182M

Similar funds

BCM
Bowie Capital Management Richardson, Texas $2.35B AUM 7.56% 1-Year Est. Return
HBT
Hills Bank & Trust North Liberty, Iowa $2.35B AUM 17.18% 1-Year Est. Return
KA
Klingman & Associates New York $2.35B AUM 23.18% 1-Year Est. Return
NPF
Norris Perne & French Grand Rapids, Michigan $2.34B AUM 32.04% 1-Year Est. Return
GCP
Greenoaks Capital Partners Orinda, California $2.36B AUM 17.42% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $2.36B AUM
HCL
Heard Capital LLC Chicago, Illinois $2.34B AUM 46.76% 1-Year Est. Return
AF
Atlas FRM Greenwich, Connecticut $2.33B AUM 3.68% 1-Year Est. Return

Oaktop Capital Management II's Q4 2019 Portfolio in Review

As of Q4 2019, Oaktop Capital Management II held 20 positions worth $381M, down 21% from $484M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Oaktop Capital Management II withdrew a net $144M in Q4 2019, closing 2 positions. Its most notable exit was Celgene Corp, an estimated $182M position sold in full.

By sector, the portfolio is most concentrated in Technology at 80% of assets, up from 56% a quarter earlier, followed by Healthcare and Materials.

Against the trend, Oaktop Capital Management II opened a new position in Bristol-Myers Squibb worth $35.6M.

  • Oaktop Capital Management II's largest Q4 2019 buy was Bristol-Myers Squibb: 554,991 shares worth $35.6M.
  • Oaktop Capital Management II fully exited Celgene Corp in Q4 2019, selling an estimated $182M.
  • Oaktop Capital Management II's ten largest holdings make up 93% of its $381M portfolio in Q4 2019.
  • Oaktop Capital Management II opened 3 new positions and closed 2 in Q4 2019.
  • Oaktop Capital Management II's portfolio value fell 21% quarter-over-quarter to $381M.

Based on Oaktop Capital Management II's 13F filing for Q4 2019, filed 3 Feb 2020.